Valuation: ValiRx plc

Market Cap 17.16L 22.9L 20.35L 18.86L 32.39L 22Cr 32.91L 2.27Cr 88.91L 11Cr 85.93L 84.1L 36Cr P/E 2024
-0.53x
P/E 2025 -0.62x
Enterprise Value 9L 12.36L 10.98L 10.18L 17.48L 12Cr 17.76L 1.22Cr 47.98L 6.12Cr 46.37L 45.38L 20Cr EV / Sales 2024
2,72,64,249x
EV / Sales 2025 5,41,21,446x
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 week-3.70%
Current month-3.70%
1 month-10.34%
3 months-18.75%
6 months-58.06%
Current year-61.19%
1 week 0.12
Extreme 0.12
0.15
1 month 0.12
Extreme 0.12
0.15
Current year 0.12
Extreme 0.12
0.48
1 year 0.12
Extreme 0.12
0.55
3 years 0.12
Extreme 0.12
14.95
5 years 0.12
Extreme 0.12
65
10 years 0.12
Extreme 0.12
968.75
Manager TitleAgeSince
Chief Executive Officer 55 12/08/2024
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 27/03/2025
Director TitleAgeSince
Director/Board Member 81 01/09/2006
Chairman 60 25/07/2024
Director/Board Member 55 12/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
04/03/26 Buy

Chief Executive Officer

10,00,000 0.1346%
18/10/22 Free

Director

75,000 0.0832%
18/10/22 Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.70%-75.24%-98.59% 22.75L
-6.60%-10.93%+45.08%+60.01% 6.9TCr
-4.09%-0.11%+2.31%+54.81% 5.31TCr
+0.03%+5.56%+10.18%+41.75% 5.08TCr
-0.99%+3.25%+30.42%+34.86% 4.46TCr
-5.80%-6.08%+258.74%+422.33% 4.06TCr
-1.56%+4.12%+16.05%+112.18% 4.25TCr
+6.53%+8.02%+18.98%+54.58% 3.09TCr
-0.90%-10.91%+34.11%-1.83% 2.54TCr
-2.50%-9.02%-16.07%-9.05% 2.27TCr
Average -1.61%+1.00%+32.46%+67.10% 3.8TCr
Weighted average by Cap. -2.39%+1.65%+45.76%+89.73%

Financials

2024 2025
Net sales 0.05 0.07 0.06 0.05 0.09 6.3 0.1 0.66 0.26 3.29 0.25 0.24 10.48 0.03 0.04 0.04 0.03 0.06 3.97 0.06 0.41 0.16 2.07 0.16 0.15 6.61
Net income -19.16L -25.56L -22.72L -21.06L -36.15L -24Cr -36.73L -2.53Cr -99.23L -13Cr -95.91L -93.87L -40Cr -22.32L -29.78L -26.47L -24.53L -42.12L -28Cr -42.8L -2.95Cr -1.16Cr -15Cr -1.12Cr -1.09Cr -47Cr
Net Debt -15.44L -20.6L -18.31L -16.97L -29.14L -20Cr -29.61L -2.04Cr -79.99L -10Cr -77.31L -75.66L -33Cr -8L -10.54L -9L -9L -14.91L -10Cr -15.15L -1.04Cr -40.93L -5.22Cr -39.56L -38.72L -17Cr
Projected Income Statement - Annual - ValiRx plc
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
11
Date Price Change Volume
16/26/16 GBX 0.1300 0.00% 14,41,783
15/26/15 GBX 0.1300 0.00% 7,32,184
14/26/14 GBX 0.1300 0.00% 47,551
13/26/13 GBX 0.1300 -3.70% 9,49,498
12/26/12 GBX 0.1350 0.00% 37,39,551

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ValiRx plc